Recursion Pharmaceuticals, Inc. SEC filings RXRX
Recursion Pharmaceuticals, Inc. has 991 filings in SEC EDGAR's recent list, going back to Apr 2, 2014. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 2, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (results of operations, officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Apr 30, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Apr 28, 2025 |
| DEFA14A | Additional proxy material | Nov 6, 2024 | — |
| DEFA14A | Additional proxy material | Oct 30, 2024 | — |
| DEFM14A | Filing | Oct 10, 2024 | — |
| DEFA14A | Additional proxy material | Sep 19, 2024 | — |
| PREM14A | Filing | Sep 17, 2024 | Sep 17, 2024 |
| DEFA14A | Additional proxy material | Sep 4, 2024 | — |
| DEFA14A | Additional proxy material | Sep 3, 2024 | — |
| DEFA14A | Additional proxy material | Aug 28, 2024 | — |
| DEFA14A | Additional proxy material | Aug 9, 2024 | — |
| DEFA14A | Additional proxy material | Aug 8, 2024 | — |
| DEFA14A | Additional proxy material | Aug 8, 2024 | — |
| DEFA14A | Additional proxy material | May 24, 2024 | — |
| DEFA14A | Additional proxy material | Apr 23, 2024 | — |
| DEF 14A | Proxy statement | Apr 23, 2024 | Jun 3, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | — |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 14, 2022 |
Showing 22 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RXRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1601830
- Former names
- Recursion Pharmaceuticals, LLC (until Dec 4, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.